SignalXSignalX

STOK Stoke Therapeutics, Inc.

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Stoke Therapeutics, Inc. Overview

Stoke Therapeutics, Inc. (STOK) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New clinical trial risk: Phase 3 EMPEROR study for zorevunersen initiated May 2025 with first patient dosed August 2025, increasing development and regulatory risk
  • • Updated regulatory risk: June 2024 U.S. Supreme Court decision on Chevron doctrine may cause increased FDA challenges and regulatory delays
+3 more insights

Get deeper insights on Stoke Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.